Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Pfeffer

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
American Heart Journal|August 30, 2001
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) TrialM A Pfeffer, M Domanski, J Verter, et al.
Quality & Safety in Health Care|August 13, 2010
Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curveJ M Taekman, M Stafford-Smith, E J Velazquez, et al.
European Heart Journal|August 17, 1999
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) RegistryB A Bart, G Ertl, P Held, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 1998
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular DiseaseA S Levey, J A Beto, B E Coronado, et al.
American Heart Journal|March 31, 2000
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsC B Granger, G Ertl, J Kuch, et al.
Journal of the American College of Cardiology|November 3, 2001
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of CardiologyS C Smith, S N Blair, R O Bonow, et al.
Circulation|September 26, 2001
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of CardiologyS C Smith, S N Blair, R O Bonow, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
American Heart Journal|August 30, 2001
The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) TrialM A Pfeffer, M Domanski, J Verter, et al.
Quality & Safety in Health Care|August 13, 2010
Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curveJ M Taekman, M Stafford-Smith, E J Velazquez, et al.
European Heart Journal|August 17, 1999
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) RegistryB A Bart, G Ertl, P Held, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 1998
Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular DiseaseA S Levey, J A Beto, B E Coronado, et al.
American Heart Journal|March 31, 2000
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsC B Granger, G Ertl, J Kuch, et al.
Journal of the American College of Cardiology|November 3, 2001
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of CardiologyS C Smith, S N Blair, R O Bonow, et al.
Circulation|September 26, 2001
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of CardiologyS C Smith, S N Blair, R O Bonow, et al.
Pageof 19